H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BioCryst (NASDAQ: BCRX) today and set a price target of $10. The company’s shares opened today at $5.92.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.6% and a 49.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Currently, the analyst consensus on BioCryst is Moderate Buy and the average price target is $8.67, representing a 46.5% upside.
In a report issued on May 5, Noble Financial also reiterated a Buy rating on the stock.
The company has a one year high of $9.25 and a one year low of $2.60. Currently, BioCryst has an average volume of 1.81M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.